Why Big Pharma Isn’t Taking Over Cannabis | TDR Cannabis in 5

The Dales Report | Trade to Black · Dec 16, 2025 · 8m

Now to today’s question: Does moving cannabis to Schedule III hand control of the industry to Big Pharma?That concern has been circulating widely, but this episode of TDR Cannabis in Five walks through why the fear doesn’t line up with how U.S. law actually works. The breakdown is based on analysis from Kyle Sherman of Flowhub, who lays out where the confusion starts — and why it keeps spreading.The core issue, as Sherman explains, is that three separate legal systems are often treated as one: the Controlled Substances Act, the FDA drug approval process, and state cannabis regulation. While…